Camp4 Therapeutics Corp (CAMP)
Camp4 Therapeutics Corp (CAMP)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -18,331 | -40,284 | -15,099 | -25,020 |
| Depreciation and amortization | 520 | 372 | 416 | 851 |
| Stock-based compensation expense | 1,472 | 1,151 | 984 | 1,863 |
| Change in fair value of derivative tranche liability | -6,188 | -28,030 | -1,800 | NaN |
| Impairment of right-of-use asset | NaN | 0 | 494 | NaN |
| Loss on the sale of property and equipment | NaN | -191 | -67 | NaN |
| Non-cash gain on lease modification | NaN | 316 | NaN | NaN |
| Non-cash lease expense | 34 | 480 | 489 | 954 |
| Non-cash interest expense | 1 | -1 | 1 | 16 |
| Prepaid expenses and other current assets | -974 | 779 | 419 | -310 |
| Accounts payable | 592 | -467 | -546 | -15 |
| Accrued expenses and other liabilities | -1,369 | 1,198 | 1,362 | -1,755 |
| Deferred revenue | -1,210 | 17,500 | 0 | -385 |
| Operating lease liabilities | -148 | 782 | 766 | 1,448 |
| Net cash used in operating activities | -10,981 | 6,293 | -11,217 | -24,629 |
| Purchases of property and equipment | 0 | 0 | 0 | 279 |
| Proceeds from the sale of property and equipment | NaN | 0 | 36 | NaN |
| Net cash used in investing activities | 0 | 0 | 36 | -279 |
| Proceeds from issuance of common stock, net of issuance costs of 3,966 and 5,747, respectively | NaN | 57,516 | NaN | 0 |
| Proceeds from issuance of common stock and pre-funded warrants, net | NaN | NaN | 32,562 | NaN |
| Proceeds from issuance of pre-funded warrants, net of issuance costs 258 | NaN | 3,601 | NaN | NaN |
| Proceeds allocated to the derivative tranche liability | NaN | 0 | 14,930 | NaN |
| Payments of deferred issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from exercise of stock options | NaN | NaN | 3 | NaN |
| Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan | 57 | NaN | NaN | NaN |
| Proceeds from exercise of common stock options | NaN | 51 | NaN | NaN |
| Principal payments on finance leases | 0 | 18 | 14 | 79 |
| Principal payments on financing obligation | 0 | 0 | 97 | 0 |
| Net cash provided by (used in) financing activities | 57 | 28,585 | 47,384 | -79 |
| Net change in cash, cash equivalents, and restricted cash | -10,924 | 34,878 | 36,203 | -24,987 |
| Cash, cash equivalents and restricted cash at beginning of period | 111,757 | 76,879 | 65,663 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 100,833 | 111,757 | 76,879 | NaN |